Advertisement


Claudio Cerchione, MD, PhD, on Staging Multiple Myeloma: New Findings on FDG PET/CT Scans and Whole-Body MRI

2024 ASCO Annual Meeting

Advertisement

Claudio Cerchione, MD, PhD, of Italy’s Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, discusses preliminary findings from a prospective trial suggesting that by adding whole-body MRI to fludeoxyglucose-18 (FDG) PET/CT scans, clinicians may detect bone lesions earlier and more accurately in patients with either newly diagnosed or relapsed multiple myeloma, thus translating into potentially better outcomes (Abstract 7512).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
In [the] last year, we have seen a great therapeutic revolution in multiple myeloma, according to many new drugs and new combination that have been approved and registered. However, I think that we should also concentrate and optimize the use of therapeutic solution and of novelties that we have seen in last years, thanks to the concentration on diagnostic tools. In this institution that we have realized, in my cancer center, we have seen the combination between whole body MRI, together with the PET FDG, which is the standard of care worldwide, both in patient newly diagnosed in relapsed refractory. And we have checked these diagnostic tools, is smoldering myeloma, as you can see in another poster presentation. Also, a task for 2024. We have seen that the combination of the double technique can totally change the journey of our patient, particularly thanks to the accuracy of whole body MRI, that is of about 97 as we have seen. And we have studied 73 patients, both newly diagnosed in the relapsed refractory. In which we have seen that in 26% of them, the combination of techniques can change their journey, particularly changing the potential treatment that we can anticipate before that signs and symptoms arise. And I think that this is particularly important because we can start to treat the patient before that he is going to suffer for myeloma pains. In particular, the combination of whole body MRI together with FDG-PET, can better characterize the bone lesion that are the main characteristic for which we treat the patient in multiple diagnosis and relapse and refractory setting. And this was the first part of the study, the radiomic part that we have presented here. But we are going to, in some way, potentiate to the study, adding a biologic characterization of our patient, in which we want to develop new biomarkers' evaluation, in the idea of having a biomarkers driven approach in next future studying metabolomic pathways. In order to start maybe to think to a dream, the personalized medicine in multiple myeloma. Which thanks to this multiomic study, we can better characterize, thanks to new generation tools our patient, and really optimize the exact drug for every patient. I think that the time is mature to concentrate on also a new prognostic score in multiple myeloma because we have seen a changing over the treatment, both in newly [inaudible 00:02:40] and the relapsed refractory setting. But we should now concentrate in changing the prognostic index that is of many years ago. This is the way to optimize all what we offer to our patient. Not only in terms of treatment, but also in terms of lifetime expectancy. And thanks to biological characterization that we are performing inside this study, we dream also to think about an MRD evaluation that could take to maybe a treatment-free remission or to optimize the dosing, dose dense and dose intensity of the drug, imagining to in some way have the patient not in ongoing treatment. And this is what they want. However, I think that the optimization of diagnostic tools can be in some way something that will help us to run toward the cure in multiple myeloma. That is not so far, and this is the best wish that we give to our patients, to their caregivers, and to all myeloma researchers around the world.

Related Videos

Breast Cancer

Lisa A. Carey, MD, and Dejan Juric, MD, on Breast Cancer: Updates From the INAVO120 Trial

Lisa A. Carey, MD, of the University of North Carolina, Chapel Hill and UNC Lineberger Comprehensive Cancer Center, and Dejan Juric, MD, of the Massachusetts General Hospital Cancer Center, discuss phase III findings on first-line use of inavolisib or placebo plus palbociclib and fulvestrant in patients with PIK3CA-mutated, hormone receptor–positive, HER2-negative locally advanced or metastatic breast cancer who relapsed within 12 months of completing adjuvant endocrine therapy (Abstract 1003).

Skin Cancer

Omid Hamid, MD, on Cutaneous Melanoma: Update on a Bispecific Protein Under Study

Omid Hamid, MD, of The Angeles Clinic and Research Institute, a Cedars-Sinai affiliate, discusses updated data on IMC-F106C, a novel bispecific protein that, in a phase I safety and efficacy study, exhibited clinical activity in patients with unresectable or metastatic cutaneous melanoma who were pretreated with immune checkpoint inhibitors. A phase III trial of IMC-F106C with nivolumab in the first-line setting of metastatic disease has been initiated (NCT06112314; Abstract 9507).

Gynecologic Cancers

Alex Andrea Francoeur, MD, on Endometrial Cancer and Obesity Trends

Alex Andrea Francoeur, MD, of UC Irvine Health, discusses data showing an association between the increasing incidence of endometrial cancer and obesity, which disproportionately affects younger women and women of color. According to Dr. Francoeur, the findings warrant targeted health services and public health interventions to stabilize and ultimately reverse the rising rates (Abstract 5507).

Skin Cancer

Christian U. Blank, MD, PhD, on Melanoma: Potentially Practice-Changing Results From the NADINA Trial

Christian U. Blank, MD, PhD, of the Netherlands Cancer Institute, discusses findings of an investigator-initiated phase III trial showing that neoadjuvant ipilimumab plus nivolumab followed by response-driven adjuvant treatment improved event-free survival in patients with macroscopic, resectable stage III melanoma compared with adjuvant nivolumab (LBA2)

Clifford A. Hudis, MD, and Karen E. Knudsen, MBA: An ASCO–American Cancer Society Partnership to Benefit Patients

Clifford A. Hudis, MD, CEO of the American Society of Clinical Oncology (ASCO), and Karen E. Knudsen, MBA, CEO of the American Cancer Society, discuss a newly launched collaboration between the organizations to make it simpler for patients to find authoritative cancer information online. The effort creates one of the largest and most comprehensive online resources for credible cancer information, available for free to the public on cancer.org.

 

Advertisement

Advertisement




Advertisement